Track market-moving stories before they get noisy

Key Takeaways

Entered into an agreement to acquire Savant Alaska, LLC for upfront consideration, plus contingent payments tied to future development of APA’s Alaska position; Acquisition includes the 40,000 barrel-per-day Badami facility plus supporting field infrastructure, and the 80,000 barrel-per-day Nutaaq Pipeline providing access to the Trans-Alaska Pipeline System;Acquired infrastructure is expected to support 2026-2027 exploration and appraisal activities, while enhancing future development flexibility; andTransaction adds approximately 104,000 gross acres and approximately 1,500 barrels of oil per day of production through interests in the Badami and Grey Owl units. HOUSTON, June 10, 2026 (GLOBE NEWSWIRE) -- APA Corporation (Nasdaq: APA) today announced an agreement to acquire Savant Alaska, LLC (“Savant”) for approximately $70 million in upfront consideration prior to customary closing adjustments, plus additional contingent payments tied to future development of APA’s eastern North Slope position.

The acquisition secures ownership of key midstream, pipeline and field infrastructure adjacent to APA’s existing acreage, and is expected to enhance development flexibility, accelerate project timelines, and lower future development costs. It also enhances APA’s ability to appraise and potentially develop discoveries across its broader eastern North Slope position.

The transaction includes the Badami facilities, which have nameplate production capacity of approximately 40,000 barrels of oil per day, along with extensive supporting infrastructure, including accommodation facilities, a grind-and-inject system, barge landing and wharf facilities, runway access, gravel resources and other field infrastructure. In addition, APA is also acquiring the Nutaaq Pipeline, which has capacity of approximately 80,000 barrels of oil per day originating at Badami and providing access to the Trans-Alaska Pipeline System. 

“The acquisition of Savant secures control of strategic infrastructure adjacent to our eastern North Slope acreage, enhancing our ability to execute our planned drilling program efficiently,” said John J. Christmann IV, APA CEO. “As we continue to appraise and de-risk our resource base, ownership of this infrastructure provides greater flexibility and optionality in future development planning and represents a key step toward unlocking the potential of our position in Alaska.” 

Several infrastructure assets, including accommodation facilities, the grind-and-inject system, barge landing and associated field infrastructure, are expected to support operations beginning with the 2026-2027 winter drilling season.  

APA has assumed operatorship of the existing joint venture with partners Lagniappe Alaska, LLC, an Armstrong company, and Oil Search (Alaska), LLC, a subsidiary of Santos Limited, and plans to conduct a two-well drilling program during the 2026-2027 winter season, consisting of one exploration well and one appraisal well. The exploration well will test a new play in the western portion of the acreage. Results from the appraisal well will help define the scale of the Sockeye complex, support development planning, and assess the feasibility of utilizing existing Badami infrastructure. 

In addition to the infrastructure assets, the acquisition includes approximately 17,000 net acres in the Badami unit, which currently produces approximately 1,500 barrels of oil per day and contains additional undeveloped resource potential. The transaction also includes approximately 75,000 net acres in the Grey Owl unit, and additional non-unitized acreage adjacent to Badami, providing further exploration upside. Following the acquisition, APA’s position on Alaska’s eastern North Slope will total approximately 487,000 gross acres.    

The transaction is expected to close by year-end 2026, subject to regulatory approval and customary closing conditions. APA will provide updated guidance post-close. 

Alaska Asset Map

About APA 
APA Corporation owns consolidated subsidiaries that explore for and produce oil and natural gas in the United States, Egypt and the United Kingdom and that explore for oil and natural gas offshore Suriname and elsewhere. APA posts announcements, operational updates, investor information and press releases on its website, www.apacorp.com. 

Forward-Looking Statements 
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by words such as “anticipates,” “intends,” “plans,” “seeks,” “believes,” “continues,” “could,” “estimates,” “expects,” “goals,” “guidance,” “may,” “might,” “outlook,” “possibly,” “potential,” “projects,” “prospects,” “should,” “upside,” “will,” “would,” and similar references to future periods, but the absence of these words does not mean that a statement is not forward-looking. These statements include, but are not limited to, statements about future plans, expectations, and objectives for operations, including statements about our capital plans, drilling plans, production expectations, anticipated benefits and closing date of the pending transaction, development plans, project timelines, and costs. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. See “Risk Factors” in APA’s Form 10-K for the year ended December 31, 2025, and in our quarterly reports on Form 10-Q for a discussion of risk factors that affect our business. Any forward-looking statement made in this news release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. APA and its subsidiaries undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future development or otherwise, except as may be required by law.   

Contacts 
Investor: (281) 302-2286 | [email protected] 
Media: (713) 296-7276 | [email protected]
Website: www.apacorp.com
APA-G 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d87f937b-ffa1-4999-8f61-a47a0b76e0b4

In the latest trading session, APA (APA - Free Report) closed at $36.78, marking a -3.21% move from the previous day. The stock's change was less than the S&P 500's daily gain of 1.75%. Elsewhere, the Dow saw an upswing of 1.86%, while the tech-heavy Nasdaq appreciated by 2.54%.

Shares of the oil and natural gas producer have appreciated by 2.79% over the course of the past month, outperforming the Oils-Energy sector's loss of 0.13%, and the S&P 500's loss of 1.63%.

The upcoming earnings release of APA will be of great interest to investors. The company is predicted to post an EPS of $1.78, indicating a 104.6% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $2.49 billion, reflecting a 4.49% fall from the equivalent quarter last year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $5.59 per share and revenue of $9.28 billion, which would represent changes of +48.28% and +0.64%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for APA. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.72% lower within the past month. APA presently features a Zacks Rank of #3 (Hold).

With respect to valuation, APA is currently being traded at a Forward P/E ratio of 6.8. This indicates a discount in contrast to its industry's Forward P/E of 9.87.

The Oil and Gas - Exploration and Production - United States industry is part of the Oils-Energy sector. At present, this industry carries a Zacks Industry Rank of 109, placing it within the top 45% of over 250 industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow APA in the coming trading sessions, be sure to utilize Zacks.com.

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ: REGN) concerning potential violations of the federal securities laws.

In March, the Senior Vice President of Investor Relations, Ryan Crowe, told investors management was "hopeful" for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS" and an "opportunity to have a statistically significant, clinically meaningful benefit on OS."

A little more than two months later, on May 16, 2026, Regeneron disclosed that fianlimab + Libtayo did not meet the trial's primary endpoint against Keytruda. The upbeat language on potential outcomes offered on March 10, 2026 failed to stress the risk of the trial failure. The stock fell sharply on the revelation.

If you suffered a loss on your Regeneron Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298727

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 15, 2026, Regeneron issued a press release disclosing that “results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma” “did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy.” 

On this news, Regeneron’s stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

Inmazeb® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients

Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity in vitro against multiple Ebola species, including Bundibugyo

Maftivimab has been recommended to be studied as a monotherapy in the current outbreak

TARRYTOWN, N.Y., May 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that maftivimab, the most potent neutralizing antibody included in Inmazeb® (maftivimab, atoltivimab and odesivimab-ebgn), has been recommended by the World Health Organization’s (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo.

The trial pertains to the WHO’s recent declaration that the current outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda constitutes a public health emergency of international concern. WHO is now working closely with the governments of DRC and Uganda to facilitate the implementation of research evaluations of the prioritized products.

“We are closely coordinating our efforts with the U.S. Department of Health and Human Services (HHS) and look forward to working with the World Health Organization and others as clinical evaluation moves ahead,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. “Regeneron has a track record of rapidly delivering important medical solutions during times of global health crisis, such as the COVID-19 pandemic and multiple Ebola outbreaks, and we know that independently run and locally executed clinical trials are critical to developing effective new medicines in such situations.”

Inmazeb is already approved by the U.S. Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, also known as Zaire ebolavirus, in adult and pediatric patients, including neonates born to infected mothers. Maftivimab is the most potent virus-neutralizing component of Inmazeb and has demonstrated broad neutralizing activity in laboratory studies against Bundibugyo ebolavirus; it has not yet been tested in vivo as a monotherapy against this distinct Ebola virus. Maftivimab has been administered to hundreds of human patients as a component of Inmazeb, which has demonstrated an acceptable safety profile. Since 2018, Inmazeb has been offered by Regeneron at no cost under a compassionate use protocol to infected persons in countries experiencing an Orthoebolavirus zairense outbreak, including the DRC and Guinea.

“Regeneron’s prior work in Ebola has shown how innovative science and groundbreaking technology platforms can be rapidly translated into life-saving medicines for people facing some of the world’s most dangerous infectious diseases,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. “As we advance our robust portfolio of transformative medicines, we always strive to do the right thing when patients and the world need urgent scientific action – whether that’s by collaborating with global health organizations to pursue new treatments or offering a life-changing new gene therapy for free in the United States.”

In September 2025, the company donated 500 doses of Inmazeb to the WHO for exclusive use by governments of low- and lower-middle income countries that are most at-risk for Ebola outbreaks.1 Regeneron has also delivered a stockpile of Inmazeb to the U.S. Government as part of HHS’s efforts to enhance national preparedness for public health emergencies. The company is closely coordinating its response efforts with the United States Government.

Regeneron is working as quickly as possible to prepare existing supply of maftivimab for use in potential upcoming clinical trials. Supply of Inmazeb is already on the ground in the DRC, should WHO wish to utilize it for immediate treatment or as an additional component of the study. Regeneron is also supporting Afya Foundation’s emergency response efforts aimed at safeguarding frontline healthcare workers and strengthening healthcare system resilience during the current outbreak.

About Inmazeb
Inmazeb is approved by the U.S. FDA for the treatment of infection caused by Orthoebolavirus zairense (also known as Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.

Inmazeb was created using Regeneron's VelocImmune® platform and associated VelociSuite® technologies. The treatment consists of three monoclonal antibodies that help neutralize the Ebola virus by blocking its ability to invade a patient’s cells and/or enlisting other immune cells to target infected cells and remove them from the body.

The safety and efficacy of Inmazeb was established through the 681-patient PALM Trial, which was independently conducted by the WHO, the National Institutes of Health (NIH) and the Institut National de Recherche Biomédicale (INRB) during the 2018 DRC outbreak. In 2019, as reported in the New England Journal of Medicine, the PALM Trial was stopped early following a pre-specified interim analysis that showed the superiority of Inmazeb in preventing death versus two other investigational treatments.

Inmazeb was approved by the FDA in 2020, and in 2022, WHO published its first guidelines for Ebola virus therapeutics, which strongly recommends the use of Inmazeb for treatment of Zaire ebolavirus infection and calls on the global community to engage all possible mechanisms to improve access to life-saving Ebola medicines. Heeding this call, in November 2023, Inmazeb became the first and only Ebola treatment to be prequalified by the WHO, certifying that the medicine meets WHO’s standards for quality, safety and efficacy and is considered “essential.” In addition to the supply channels established in the U.S. and low- and lower-middle income countries, Regeneron has also worked with governments in higher- and middle-income countries to establish Inmazeb stockpiles.

Inmazeb was developed in collaboration and with federal funds from BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the HHS under ongoing USG Contract Nos. HHSO100201700016C and HHSO100201500013C.

IMPORTANT SAFETY INFORMATION AND INDICATION
WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Infusion-Associated Events: Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with INMAZEB. These may include acute, life-threatening reactions during and after the infusion. Monitor all patients for signs and symptoms including, but not limited to, hypotension, chills and elevation of fever, during and following INMAZEB infusion. In the case of severe or life-threatening hypersensitivity reactions, discontinue the administration of INMAZEB immediately and administer appropriate emergency care.

Infusion could not be completed in 1% of subjects who received INMAZEB due to infusion-associated adverse events. The rate of infusion of INMAZEB may be slowed or interrupted if the patient develops any signs of infusion-associated events or other adverse events.

ADVERSE REACTIONS: The most common adverse events reported in at least 20% of subjects who received INMAZEB were pyrexia (or elevation in fever), chills, tachycardia, tachypnea and vomiting. The evaluation of adverse events in subjects who received INMAZEB may have been confounded by the signs and symptoms of the underlying Orthoebolavirus zairense infection.

DRUG INTERACTIONS: INMAZEB may reduce the efficacy of live vaccine therefore, avoid the concurrent administration of a live vaccine during treatment with INMAZEB. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. The efficacy of INMAZEB among subjects who reported receipt of a recombinant live vaccine prior to their enrollment in the PALM clinical trial was similar to subjects who did not receive a vaccine.

INDICATION
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.

Limitations of Use: The efficacy of INMAZEB has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera. Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding to use INMAZEB.

Please see accompanying full Prescribing Information.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Inmazeb® (maftivimab, atoltivimab and odesivimab-ebgn) and maftivimab (an antibody included in Inmazeb); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, such as maftivimab for the treatment of Bundibugyo ebolavirus as discussed in this press release; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab); the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business (including the current Bundibugyo ebolavirus outbreak referenced in this press release); the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab) in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025 and its Form 10-Q for the quarterly period ended March 31, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Regeneron Contacts:

Media Relations
Alexandra Bowie
Tel: +1 (914) 847-3407
[email protected]  

Investor Relations
Mark Hudson
Tel: +1 914-847-5443
[email protected]

___________________
1 As defined by the World Bank based on gross national income per capita.

A month has gone by since the last earnings report for Regeneron (REGN - Free Report) . Shares have lost about 12.1% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Regeneron due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts.

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength

Regeneron reported first-quarter 2026 adjusted earnings per share (EPS) of $9.47, which beat the Zacks Consensus Estimate of $8.52 and increased from $8.22 recorded in the year-ago quarter.

The strong bottom-line performance was driven by higher revenues and a reduced share count.

Total revenues grew 19% year over year to $3.6 billion, driven by higher sales of Eylea HD and increased Dupixent profits.

Revenues also beat the Zacks Consensus Estimate of $3.4 billion.

Eylea HD and Dupiexent Power REGN’s Q1 Results

The lead drug, Eylea, is approved for various ophthalmology indications (neovascular age-related macular degeneration, diabetic macular edema and macular edema, among others).

Eylea’s sales in the United States plunged 36% year over year to $473 million, primarily due to increased competition from other drugs like Roche’s Vabysmo and continued transition of patients to higher doses of the drug (Eylea HD). Eylea sales in the United States beat the Zacks Consensus Estimate of $436 million.

Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG. Regeneron records net product sales of Eylea and Eylea HD in the United States, while Bayer does the same outside the country. The company recorded its share of profits in connection with Eylea and Eylea HD sales outside the United States within collaboration revenues.

In August 2023, the FDA approved Eylea HD (a higher dose of Eylea) for the treatment of patients with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.

Eylea HD generated revenues of $468 million in the United States, up 52% year over year, backed by higher sales volumes and increased demand. However, sales were negatively impacted by lower wholesaler inventory levels at the end of the first quarter of 2026 compared to fourth-quarter 2025 levels. Eylea HD sales beat the Zacks Consensus Estimate by 0.12%.

Total revenues include collaboration revenues of $1.9 billion from Sanofi and Bayer. The figure increased 24% from that recorded in the year-ago quarter. Total collaboration revenues beat the Zacks Consensus Estimate of $1.86 billion.

Sanofi’s collaboration revenues increased 36% to $1.6 billion, driven by profits associated with higher Dupixent sales. The figure beat the Zacks Consensus Estimate of $1.5 billion. We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs within collaboration revenues. Dupixent’s sales increased 33% year over year to $4.9 billion.

Bayer’s collaboration revenues totaled $287 million, down 17% year over year.
Regeneron records net product sales of Praluent in the United States, while Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales of Libtayo and pays Sanofi a royalty on such sales.

Total Libtayo sales were $438 million, up 54% year over year. The figure beat the Zacks Consensus Estimate of $361 million.

Praluent’s net sales in the United States were $67 million.

The FDA had earlier approved linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The drug was granted accelerated approval by the FDA under the brand name Lynozyfic. It is also approved in the EU to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Lynozyfic sales came in at $11 million.

A Look at REGN’s Q1 Expense Summary

Gross margin on net product sales inched up to 86% from 85%.

Adjusted R&D expenses increased 19% year over year to $1.4 billion due to the advancement of the company's pipeline, including programs in hematology-oncology, complement-mediated diseases and anticoagulation. Adjusted SG&A expenses increased 4% to $560 million due to an increase in commercialization-related expenses for Eylea HD and Libtayo and higher headcount and headcount-related costs.

During the first quarter of 2026, the company repurchased $803 million worth of its common stock. As of March 31, 2026, $688 million remained available under its existing share repurchase programs.

In April 2026, the board authorized a new program for up to an additional $3.0 billion in share buybacks.

REGN’s Key Pipeline and Regulatory Updates

In April 2026, the FDA and European Commission approved Dupixent for the treatment of chronic spontaneous urticaria (CSU) in children aged two to 11 who remain symptomatic despite antihistamine treatment. This expands the previous approvals in the United States and EU for CSU in adults and adolescents aged 12 and older.

In February 2026, the FDA approved Dupixent as the first and only medicine for the treatment of adults and children aged six and older with allergic fungal rhinosinusitis.

In April 2026, the FDA approved extending Eylea HD dosing intervals up to 20 weeks for wAMD and DME patients after one year of sustained response, further enhancing its dosing flexibility among anti-VEGF therapies.

The company also resubmitted its application for the Eylea HD pre-filled syringe (PFS) at the Bloomington, Indiana site (formerly Catalent Indiana LLC), now fully owned and operated by Novo Nordisk, following a re-inspection. 

A decision on a second PFS manufacturing application was not made by the April 2026 target action date and remains under review. REGN expects a regulatory update on one or both applications in the second quarter of 2026.

The FDA recently granted accelerated approval to Otarmeni (lunsotogene parvec, formerly DB-OTO), the first gene therapy cleared under the FDA Commissioner’s National Priority Voucher Program. The adeno-associated virus-based treatment is indicated for pediatric and adult patients with severe-to-profound hearing loss caused by OTOF gene variants.

The company submitted a new drug application seeking FDA approval of cemdisiran in myasthenia gravis using a rare pediatric disease priority review voucher.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

VGM ScoresCurrently, Regeneron has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. Charting a somewhat similar path, the stock has a score of B on the value side, putting it in the top 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Interestingly, Regeneron has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

(We are reissuing this article to correct a mistake. The original article, issued on May 29, 2026, should no longer be relied upon.)

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 15, 2026, Regeneron issued a press release disclosing that “results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma” “did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy.” 

On this news, Regeneron’s stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 15, 2026, Regeneron issued a press release disclosing that "results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." 

On this news, Regeneron's stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

Regeneron Pharmaceuticals remains a "Buy," driven by EYLEA HD expansion, strong DUPIXENT growth, and promising pipeline assets. EYLEA HD U.S. sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. Recent FDA approvals and pending regulatory decisions for EYLEA HD and CEMDISIRAN provide near-term catalysts and franchise durability.

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Regeneron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 15, 2026, Regeneron issued a press release disclosing that “results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma” “did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy.” 

On this news, Regeneron’s stock price fell $68.57 per share, or 9.82%, to close at $629.68 per share on May 16, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Regeneron issued a press release on May 15, 2026, revealing that “results from the Phase 3 trial evaluating two dose levels of fianlimab (LAG-3 inhibitor) in combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma” failed to achieve statistical significance “for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy.” Based on this news, shares of Regeneron fell by more than 9.8% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610917236/en/

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Regeneron (REGN - Free Report) Tarrytown, NY-based Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting severe medical conditions. The company’s portfolio includes Eylea (for several eye diseases), Eylea HD (higher dose of Eylea), partnered drug Dupixent (asthma, atopic dermatitis and chronic rhinosinusitis with nasal polyposis, chronic obstructive pulmonary disease, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria), Libtayo (lung cancer, advanced basal cell carcinoma, metastatic or locally advanced cutaneous squamous cell carcinoma, cervical cancer), Praluent (heterozygous familial hypercholesterolemia and homozygous familial hypercholesterolemia), Kevzara (moderately-to-severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis), Evkeeza (homozygous familial hypercholesterolemia), Ordspono, (follicular lymphoma and diffuse large B-cell lymphoma), I Lynozyfic (relapsed/refractory multiple myeloma) Inmazeb (Ebola), Veopoz (CHAPLE disease), Arcalyst and Zaltrap. 

REGN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.28; value investors should take notice.

Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $1.77 to $46.05 per share. REGN also boasts an average earnings surprise of +26.3%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, REGN should be on investors' short list.

Few events on Wall Street are more telling than the quarterly filing of Form 13Fs with regulators. A 13F allows investors to track which stocks Wall Street's savviest money managers purchased and sold in the latest quarter. In other words, it can help investors identify the stocks and trends piquing the interest of the most successful investors.

I analyzed the top four holdings by market value of more than a dozen billionaire investors for the first quarter, and surprisingly, some of Wall Street's most influential businesses, such as Nvidia, Apple, and Microsoft, weren't common denominators.

Image source: Getty Images.

These are billionaires' favorite stocks The following five stocks are the most commonly held (i.e., favorite) top holdings by billionaire money managers:

Amazon (AMZN 1.24%): held by six billionaires (David Tepper, Dan Loeb, Seth Klarman, Chase Coleman, Bill Ackman, and Larry Robbins) Taiwan Semiconductor Manufacturing (TSM +0.46%): held by four billionaires (Philippe Laffont, Chase Coleman, Ole Andreas Halvorsen, and Stanley Druckenmiller) Alphabet (GOOGL +0.53%)(GOOG +0.44%): held by two billionaires (David Tepper and Chase Coleman) Uber Technologies (UBER 1.01%): held by two billionaires (David Tepper and Bill Ackman) Visa (V +0.93%): held by two billionaires (Terry Smith and Ole Andreas Halvorsen) Why these five companies? Look no further than their sustainable moat and their integration of artificial intelligence (AI).

Billionaire fund managers gravitate to industry leaders The one factor all five of these businesses have in common is their undisputed status as industry leaders.

For instance, not only is Amazon a dominant e-commerce player, but Amazon Web Services (AWS) is the world's No. 1 cloud infrastructure services platform by total spend.

Today's Change

(

-1.24

%) $

-2.98

Current Price

$

238.53

Though the other companies on this list aren't dual-industry leaders, their respective spots atop the pedestal are secure:

Alphabet's Google accounts for approximately 90% of worldwide internet search traffic. Uber controls in the neighborhood of three-quarters of the U.S. ride-share market. Taiwan Semi is the world's leading chip fabricator (including graphics processing units). Visa is the runaway domestic leader in credit card network purchase volume. Good things often happen for businesses that can maintain their competitive advantages.

Image source: Getty Images.

Billionaires want in on the AI revolution The other common denominator among billionaire investors is their desire to aggressively invest in the leaders of the AI revolution.

As noted, AWS is the world's top cloud infrastructure services platform, with Alphabet's Google Cloud No. 3 by total spend. Both AWS and Google Cloud have integrated generative AI solutions and large language model capabilities into their respective platforms, leading to a reacceleration in their growth rates. AWS grew sales by 28% in the March-ended quarter, while Google Cloud produced a 63% jump in revenue.

Today's Change

(

0.53

%) $

1.90

Current Price

$

359.67

Taiwan Semiconductor Manufacturing is enjoying a substantial backlog for advanced chip fabrication, as well as the exceptional pricing power that comes with demand for its services outstripping supply.

While Uber doesn't have AI ties as clear as those of Amazon, Alphabet, or Taiwan Semi, it's very much an AI-driven business. Uber leans heavily on AI to match riders with drivers, optimize routes, and maximize profits via dynamic pricing.

Sean Williams has positions in Alphabet, Amazon, and Visa. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Microsoft, Nvidia, Taiwan Semiconductor Manufacturing, Uber Technologies, and Visa. The Motley Fool has a disclosure policy.

Tesla (NASDAQ:TSLA | TSLA Price Prediction) CEO Elon Musk dropped a striking claim during a recent conversation with Baron Capital founder Ron Baron, circulated widely after being posted to X by @carm1nee. Musk said he is building a chip that will be “two to three times better than NVIDIA” at 10% of the cost, with a specific focus on inference workloads.

The boast lands at a sensitive moment for the AI chip trade. NVIDIA (NASDAQ:NVDA) commands a $5.02 trillion market cap and posted Q1 FY2027 revenue of $81.61 billion, while Intel (NASDAQ:INTC) has surged on a foundry comeback that includes a Tesla partnership.

The question is whether Musk is laying out a real roadmap or projecting ambition that won’t survive execution timelines. The answer requires looking at his track record on both sides of that ledger.

Musk’s Bold Claim, Broken Down Musk asserted that he can “visualize” the entire physical chip design and that Tesla’s next-generation processors will beat NVIDIA at inference by a wide margin. He also brushed off Taiwan Semiconductor Manufacturing‘s (NYSE:TSM) claim that a new fab takes five years.

“Five years to me is an eternity,” Musk declared. “My timelines go one year, two year, and at year three it goes to infinity.” He framed the chip as critical to scaling Tesla’s autonomy, citing 10 billion miles of Full Self-Driving (FSD) data and claiming the system is already “4 times safer than a human driver” with a 10x improvement coming.

The substance behind the claim is the AI5 inference chip, which Tesla taped out in April. Production is planned for 2027, with AI6 following in 2028 and Tesla targeting a 50x improvement over AI4. TSLA stock is down 10.5% year to date (YTD), suggesting investors haven’t fully priced this roadmap in.

Terafab and the Vertical Integration Bet The manufacturing side runs through Terafab, the joint chip-fab initiative Musk announced with Tesla in March, with Intel joining as a partner in April. The SpaceX S-1 filing describes a long-term goal of producing “one terawatt of compute hardware each year” with chips designed for both terrestrial and orbital AI deployments.

Intel’s Q1 FY2026 results show why Musk wanted it in the tent. The Intel Foundry segment grew to $5.42 billion (up 16% year over year), and Intel 18A is now in high-volume manufacturing in Arizona and Oregon. Musk has said Terafab will use Intel’s 14A process.

Intel CEO Lip-Bu Tan has called Intel “a fundamentally different company,” with AI-driven businesses contributing 60% of revenue. INTC stock is up 195% YTD on the foundry revival, Apple (NASDAQ:AAPL) manufacturing rumors, and a nearly 10% U.S. government stake.

The SpaceX S-1 filing frames Terafab as in-house vertical integration for Musk’s own companies rather than a commercial foundry chasing Taiwan Semiconductor’s external customer book. Whether the closed-loop model can beat the world’s most advanced foundry on cost per usable chip remains the central question.

Why NVIDIA Still Has the High Ground NVIDIA’s most recent earnings report shows the gap any challenger must close. The company’s revenue rose 85% YoY, data center revenue hit $75.25 billion (+92%), and non-GAAP gross margin came in at 75% (see the Q1 FY27 release). NVIDIA CEO Jensen Huang called the AI factory buildout “the largest infrastructure expansion in human history.”

The Vera Rubin platform, NVIDIA’s Blackwell successor, claims a 10x reduction in inference token cost. That matters because inference is the workload Musk says Tesla can beat NVIDIA on, and NVIDIA is racing its own roadmap directly into that argument.

NVDA stock trades at a forward P/E ratio of 23x with an average analyst target of $298. The bear case is the one Michael Burry has voiced, calling the Musk-NVIDIA dynamic a “Fugazi” while questioning AI infrastructure pricing power.

Is He Bluffing? Weighing the Track Record Musk’s history cuts both ways. He delivered reusable rockets and scaled Tesla into the world’s most valuable automaker. However, his FSD timelines have slipped repeatedly, and the “year three goes to infinity” pacing has often proven more aspirational than predictive in the autonomy business.

The prediction markets implicitly side with skepticism. Polymarket has no active markets on Tesla’s chip milestones, and the Tesla-xAI merger market sits at 99% “No” probability by June 30, suggesting that traders aren’t pricing near-term validation of Musk’s integrated compute thesis.

Investors can hold both ideas at once. NVIDIA’s moat is enormous and self-reinforcing, while Tesla’s AI5, AI6, and Terafab work could legitimately reshape inference economics if even half of Musk’s claims land. Watch for whether AI5 production timelines hold in 2027 and whether Intel 14A yields support Terafab’s cost math, and then form your own judgment on the rest.

Taiwan Semiconductor Manufacturing Company TSM reported May 2026 consolidated net revenue of NT$416.975 billion ($13.17 billion), up 30.1% from May 2025 and 1.5% from April 2026. Cumulative revenue for January through May 2026 reached NT$1,961.804 billion ($62 billion), a 30.0% increase compared to the same period last year.

The results extend TSMC's streak of robust year-over-year growth, driven by sustained demand for advanced chips used in AI infrastructure, smartphones, and high-performance computing.

TSMC's numbers land as the broader AI trade takes a breather. The Nasdaq fell 4% last Friday, its worst session since early 2025, as investors began reassessing chip valuations. The monthly figures failed to lift sentiment, with shares down 2.60% in premarket despite the strong numbers.

TSM Reports Strong May Revenue, Yet Stock Declines Amid Semiconductor Weakness

Taiwan Semiconductor Manufacturing TSM is experiencing a decline in its stock price despite announcing impressive May revenue of NT$416.98 billion. This figure represents a 1.5% increase from April and a substantial 30.1% year-over-year growth. For the first five months of 2026, revenue rose 30.0% year-over-year to NT$1.962 trillion. Although the monthly sales report was robust, investors seem to be taking profits and reacting to a general downturn in the semiconductor sector rather than celebrating TSM’s continued growth driven by AI.

Run-rate support: The May sales performance aligns well with TSM's Q2 revenue guidance of $39.0-$40.2 billion, a notable increase from Q1's actual revenue of $35.9 billion. Recent execution: In Q1, TSM reported earnings per share (EPS) of $3.49, surpassing the FactSet consensus of $3.30, with revenue reaching $35.9 billion against an expectation of $35.35 billion, showcasing solid operational execution amid strong demand for advanced nodes. Advanced-node strength: The demand for AI and high-performance computing continues to drive growth, with 3nm technology contributing to 25% of Q1 wafer revenue and advanced technologies at 7nm and below accounting for 74% of total wafer revenue. AI demand backdrop: Management previously indicated that global chip supply will not meet AI-chip demand in the coming years, which supports a long-term bullish outlook despite the current stock weakness. Valuation watch: The stock had already seen a rally leading up to the May sales report and was trading near recent highs. This strong monthly performance may not have been sufficient to counteract profit-taking, broader tech sector weakness, and concerns that AI-related expectations are already priced in. The recent decline in TSM's stock does not alter the fundamental message from its May revenue report, which indicates strong demand for AI, high-performance computing, and advanced-node technologies. However, it suggests that investors are now more cautious, requiring stronger performance to justify positive stock movement, especially in a challenging semiconductor environment. While May revenue confirms the Q2 run-rate, it does not imply a new guidance increase; the significant outlook adjustment occurred in April when management raised its 2026 revenue growth forecast and indicated capital expenditures at the high end of the previous range. Investors are likely balancing strong demand visibility against high expectations and significant capital investments, aware that any slowdown in monthly growth could lead to more severe stock reactions, particularly given the well-understood AI foundry narrative.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Marley Kayden talks about May's CPI beating expectations marking the highest number we've seen in three Years. Sam Vadas discusses TSMC (TSM) May revenue rising despite the company falling below analysts' expectations.

CompaniesTAIPEI, June 12 (Reuters) - The head of Taiwan's TSMC (2330.TW), opens new tab, the world's largest contract chipmaker, said on Friday that what his company lacks most is talent, while also worrying about ​water shortages.

Taiwan produces most of the advanced chips powering the AI revolution, but ‌the industry has long complained about what executives call the "five shortages" - water, power, labour, land and talent.

The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.

Speaking at a rain-drenched ceremony for a new science park in southern Taiwan's Pingtung, TSMC CEO ​C.C. Wei said he was happy about the weather.

"Just last month, I ​was still wondering: What should we do about water? Should we ⁠start using water trucks?" he said in comments carried live on Taiwan television networks.

Wei ​said Taiwan President Lai Ching-te, who was present at the event, had told him ​of government plans to connect the island's reservoirs together.

"In that case, in the future I will no longer need to say that land, water or electricity may be in short supply," Wei said.

Reservoirs ​in much drier southern Taiwan generally drop over the winter, though heavy rain ​in the past week has helped replenish them. In 2021, Taiwan imposed widespread water controls after the worst ‌drought ⁠in its history.

The logo of Taiwan Semiconductor Manufacturing Company (TSMC) is displayed at TSMC Museum of Innovation in Hsinchu, Taiwan April 9, 2026. REUTERS/Ann Wang/File Photo Purchase Licensing Rights, opens new tab

"We may face shortages, but what we still lack most is talent," Wei added, calling on efforts to train more workers and keep people in largely rural Pingtung.

Lai, speaking after Wei, said the government was close to completing its plans ​to link reservoirs.

"Our problem ​is how to ⁠retain water, how to distribute water, and how to use water efficiently," Lai added.

He also outlined how the government is trying ​to attract and retain foreign talent in particular to help the ​tech industry, ⁠including by easing work permit applications.

While TSMC, a major supplier to Nvidia (NVDA.O), opens new tab, is investing $165 billion to build factories in the U.S. state of Arizona, the company has repeatedly said most ⁠of ​its production, along with research and development, will remain ​in Taiwan.

Wei said semiconductors have become "inseparable" from everything, and demand will continue to grow.

"Regarding semiconductors, Taiwan will ​definitely be the most important place," he said.

Reporting by Ben Blanchard; Editing by Kevin Buckland

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Taiwan manufacturing capacity Taiwan is the world’s most critical semiconductor manufacturing hub. In 2025 its economy grew by 8.68% and it exported around $550B, growing at a staggering rate of 34% YoY. Electronics traditionally represent around 33% of the total. With the increase in CAPEX by the American and Chinese AI industry, the Taiwanese exports are becoming critical for the whole supply chain.

This hyper specialized semiconductor ecosystem is what makes the island so strategically attractive for the leading-edge AI companies and investors alike. No other country combines Taiwan’s semiconductor expertise, equipment and talent on this scale. The evidence is in the numbers, with a 90% global market share for leading-edge chip production.

Taiwan´s industry is deeply integrated, and as the big manufacturers grow, so do the medium and small ones. TSMC ($TSM) might be the most well-known name, as it is also the largest company in Taiwan. The company provides advanced manufacturing services for the fabless chip companies. TSMC is the de facto manufacturing partner for Nvidia, Apple, Google, and leading chip designers. While the company operates fabs in the U.S., Japan, and China, the most advanced fabs with the largest capacity are located in Taiwan. 

TSMC and the semiconductor ecosystem Rising demand for TSMC’s products is forcing its suppliers to scale up in parallel. This creates a multiplier effect across the broader Taiwanese supply chain. As TSMC scales to meet AI demand, hundreds of local suppliers, from wafer polishers to packaging firms like ASE, silicon providers like GlobalWafers, and substrate manufacturers like Unimicron, also do. Virtually all of the big suppliers sit inside EWT and FLTW, which is precisely what makes these ETFs a leveraged bet on Taiwan’s entire AI supply chain, not just its most famous chip maker.  

The Taiwanese synergy Material Suppliers For foundries Taiwanese industry leaders are deeply intertwined. TSMC, for instance depends on GlobalWafers (6488.TWO), a key silicon wafer supplier, used for chips manufacturing. Globalwafers is the only silicon wafer Taiwanese supplier with a presence in the EWT ETF with a documented relationship with TSMC. In the period of 2018 to 2020, GlobalWafers was one of the 6 main silicon wafer providers used by TSMC to cover 92% of its needs. Moreover, in March 2025 the company further deepened this tie by announcing the co-location of a new manufacturing facility to support TSMC’s Arizona fab.

From Design to Manufacturing The relationship between MediaTek and TSMC illustrates how deeply intertwined Taiwan’s semiconductor leaders are. Mediatek (2454.TW), Taiwan’s leading fabless chip designer, uses TSMC as their primary foundry. In Q4 2025, Mediatek announced it had adopted TSMC’s 2nm for its next flagship system-on-a-chip (SoC). The chip is expected to enter mass production in the second half of 2026 for use in mobile devices. 

The strategic depth of this partnership goes beyond manufacturing. In May 2026, Mediatek CEO Joe Chen reaffirmed TSMC as a key long-term partner. He noted collaboration across nodes from 12nm, down to the next generation of 1.4nm. Moreover, he added the joint work in advanced packaging, optical packaging and Co-packaged optics (CPO).

From Foundry to  advanced packaging The synergy within Taiwan’s semiconductor industry is perhaps most visible between TSMC and ASE Technology Holdings (3711.TW), the world’s largest semiconductor assembler and tester. ASE provides assembly and packaging services, a critical step in delivering finished chips to market. 

One of ASE’s highest-margin offerings is  Chip-on-Wafer-on-Substrate (CoWoS). The demand for CoWoS is expected to exceed global capacity through 2026. As TSMC’s own packaging capacity runs constrained, OSAT partners like ASE absorb the excess in demand. 

TSMC is tying the whole Taiwanese ecosystem. In 2018, TSMC identified that less than half of the spare parts and raw materials in its Taiwanese facilities were locally sourced. In response to that, TSMC launched the “Parts Localization and Innovation Program” in 2024. The program aims at increasing supply chain resilience and reducing dependence on overseas suppliers. The initiative plans to reach 68% of raw materials and 60% of locally sourced components by 2030.

Early results are already visible, In January 2026, TSMC assisted a Japanese supplier to locally produce electroplating additives to be used in Fab 2,3,5,6, and 8. The company expects that these efforts reduce the production cycle from 60 days to just 20.

TSMC is also deepening the semiconductor ecosystem through supplier development programs.  As of February 2026, TSMC collaborated with 12 suppliers to develop 22 Continued Improvement Processes. This signals that the TSMC efforts are also raising the capabilities of Taiwan’s industrial base.

NVIDIA GTC 2026 and Taiwan’s moment NVIDIA’s CEO, Jensen Huang has expressed in several interviews the relevance of Taiwan for Nvidia and the whole AI ecosystem. At the GTC 2026 he declared ‘Taiwan is the epicenter of the AI revolution. This is where the chips come, packaging comes, this is where the systems are made, this is where AI supercomputers were created. The number of partners we work with here in Taiwan, incredible.’ 

The company plans to keep expanding its investments in Taiwan, with projections pointing toward $150B per year. That would mean a 10-fold increase since 2021. As those investments materialize, the capital is likely to flow from NVIDIA’s largest suppliers into the whole Taiwanese semiconductor industry.

ETFs to capture the momentum The Taiwanese industry is so deeply integrated that measuring the AI buildout impact on a single company is nearly impossible, and perhaps unnecessary. For investors seeking broad exposure to Taiwan’s AI momentum, two of the most relevant ETFs are EWT and FLTW. 

EWT, launched by Blackrock in June 2000, tracks MSCI Taiwan 25/50 index. A market-cap-weighted index of Taiwanese companies representing approximately 85% of the country’s investable equity market. 

FLTW, launched in November 2017, follows the FTSE Taiwan RIC Capped Index. The Index focuses on large- and mid-cap stocks while excluding small-cap firms. 

Over the past year, both ETFs have delivered exceptional returns, averaging approximately 90%, due to Taiwan’s exposure to the AI buildout.

Key differences While both ETFs provide concentrated exposure to Taiwan’s largest companies, they differ on structure and cost. EWT, with $10.5B in AUM is larger than FLTW $2.8B. The gap directly translates to tighter spreads and higher daily trading volume. For EWT the volume is around 5.8M versus 1M for FLTW. For active traders the liquidity difference could be meaningful. 

However, for long-term investors, FLTW makes a compelling case. Its expense ratio of 0.19% versus 0.59% may seem minor, but on a $100K investment over 20 years that 0.40% annual gap compounds to $30K. Not only that, the 5 year annualized return for FLTW is higher at 21.2%, versus 18.0% for EWT. On top of that, the broader diversification of FLTW with 135 positions compared to just 87 from EWT. 

Despite the differences, both ETFs share the same top positions : TSMC, Mediatek, Delta Electronics, Hon Hai Precision and ASE technology. Moreover, both ETFs have delivered near-identical YTD returns in 2026, approximately 68%.

Risks These ETFs carry at least four key risks worth acknowledging: the geopolitical tension, the susceptibility to natural disasters on Taiwan, the heavy concentration in TSMC (20% of both funds) and dependence on the AI CapEx cycle .
Geopolitical risk remains the most difficult to quantify. Any conflict materialization would be catastrophic for both ETFs.

Taiwan is prone to natural disasters. The island experiences approximately 2000 earthquakes per year, 200 being perceptible. In April 2024 a 7.2 magnitude earthquake caused $92M in losses for TSMC alone, reducing Q2 2024 gross margins by 0.5 percentage points. 

Finally a heavy concentration in TSMC and a potential slowdown in AI CapEx spending, would likely produce a selloff in both ETFs.

Valuation framework After one of the strongest rallies in either ETFs historic performance, the question is whether the market has already priced the best-case outcome. The following framework uses earnings data to estimate current valuations and identify what needs to happen before adding exposure.

AI revenue exposure, gross margin and total revenue Company

EWT weight

FLTW weight

Gross Margin Q1’26

AI revenue Share

Q1’26 revenue

AI revenue Q1’26

TSMC

20.7%

19.9%

66.2%

61%

$35.9B

$21.9B

Delta Electronics

5.1%

6.4%

37.0%

30%

$5.0B

$1.5B

Mediatek

6.3%

5.2%

46.0%

5%

$4.7B

$0.75B

ASE technology

2.6%

2.4%

20.1%

15%

$5.5B

$0.8B

Hon Hai

3.9%

5.5%

6.2%

48%

$66.6B

$32B

AI revenue exposure, gross margin & total revenue — top 5 shared holdings . Note: HonHai cloud & networking segment includes AI servers  

TSMC guidance full-year 2026 revenue growth above 30%. The combined confirmed AI-related revenue across the largest five shared holdings yields an estimated $228B annualized. This represents just a fraction of the ETF’s total annualized revenue, and better captures the exposure to the AI Infrastructure buildout. 

Valuation scenarios In December 2025, EWT traded at 20x earnings. By Q1 2026, the valuation expanded to 31.8x, 59% appreciation in just one quarter. The market is already pricing a revenue surge. 

Case

Bull case

Base case

Bear case

Earnings growth

+35%

+25%

+15%

Implied fair P/E

28-32x

22-25x

16-18x

Hyperscaler CapEx

+$670B

+$600B

+$500B

PEG

0.91

1.27

2.12

At 31.8x earnings, the ETFs are already pricing in the bull case. Under the base case of 25% earnings growth, the PEG ratio climbs to 1.27. This implies that the ETFs are trading 20% above the fair value. A deceleration to just 15% growth would imply 35-40% downside. The key variable across all three scenarios is whether TSMC’s 30% growth guidance holds through the year, which is tied to the hyperscaler CapEx commitments above $670B holding true for the second half of 2026.

Conditions that would change the entry case The most direct input into the bull case is whether the four major hyperscalers maintain or raise their combined CapEx commitments above $670B. Delta electronics CFO cited the figure on Q1 2026 as the determining factor behind the company’s record margins. If the spending holds or increases, TSMC’s own 30% growth guidance embedded within the current P/E is plausible. If the spending is reduced, the base case of 1.27 becomes more probable. 

Second, TSMC gross margin is a good indicator to hold the bull case intact. The company reported 66.2% in Q1’26 and guided for Q2 65.5%-67.5%. A result in that range would signal the narrative is maintained, while a result below 62%, Q4 ’25 level, would suggest guidance predictions are overestimating and the growth story might lag. 

Third, a degradation of the P/E to historical range, from 22-25x would represent a materially better entry point. At 22x EWT would trade near $70, at 25x near $80. In that range, with the bull case intact, the PEG would drop to 0.72-0.83, making the entry case compelling. 

A fourth condition is less predictable but worth monitoring. In March 2026, Elon Musk announced Terafab. An ambitious project to build Tesla and SpaceX’s own chip fabrication facility. Musk chose Intel’s 14A process over TSMC. If Terafab struggles to execute, the most likely scenario would reinforce TSMC’s irreplaceability and drive additional demand back to Taiwan’s ecosystem.  

The Takeaway At current levels, both ETFs are priced for perfect execution. For investors already holding positions, the framework suggests monitoring TSMC gross margin and revenue during Q2 2026. For investors considering initiating a position, the $70-80 range on EWT represents an attractive level. 

Authors opinion Taiwan is the world’s most critical semiconductor manufacturing hub and indispensable for the AI supply chains. Last year its economy grew at a staggering rate of 8.68% and its exports surged 34%. The momentum shows no signs of slowing as hyperscalers deepen their commitments to the island. Nvidia alone has announced plans to spend $150B per year in Taiwan.
TSMC’s initiatives aim to further integrate the ecosystem, to reduce costs, environmental impact and increase resilience to geopolitical factors. 

For investors, EWT and FLTW offer two efficient entry points into Taiwan’s semiconductor manufacturing momentum. The thesis is intact, as the AI buildout continues, Taiwan’s ecosystem is structurally positioned to capture a disproportionate share of that growth. Nonetheless, At 31.8x earnings,  both ETFs are pricing in perfect execution. Watch TSMC’s Q2 gross margin and hyperscaler CapEx guidance: if either disappoints, the $70–80 range on EWT becomes the entry point where conviction and price finally align. 

Abbott (ABT - Free Report) closed the most recent trading day at $85.68, moving -1.14% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.02%. At the same time, the Dow added 0.36%, and the tech-heavy Nasdaq gained 0.07%.

Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 7.66% lagged the Medical sector's gain of 2.02% and the S&P 500's gain of 5.12%.

The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. The company is predicted to post an EPS of $1.28, indicating a 1.59% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $12.53 billion, reflecting a 12.43% rise from the equivalent quarter last year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $5.48 per share and revenue of $50.49 billion, indicating changes of +6.41% and +13.9%, respectively, compared to the previous year.

Investors should also pay attention to any latest changes in analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.42% lower. Abbott is currently sporting a Zacks Rank of #4 (Sell).

Valuation is also important, so investors should note that Abbott has a Forward P/E ratio of 15.82 right now. This valuation marks a discount compared to its industry average Forward P/E of 18.69.

We can also see that ABT currently has a PEG ratio of 1.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. ABT's industry had an average PEG ratio of 1.5 as of yesterday's close.

The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 160, placing it within the bottom 35% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Abbott (ABT - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this maker of infant formula, medical devices and drugs have returned -5%, compared to the Zacks S&P 500 composite's +6% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has lost 6.7%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Abbott is expected to post earnings of $1.28 per share, indicating a change of +1.6% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.1% over the last 30 days.

The consensus earnings estimate of $5.48 for the current fiscal year indicates a year-over-year change of +6.4%. This estimate has changed -0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $6.06 indicates a change of +10.6% from what Abbott is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Abbott is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Abbott, the consensus sales estimate of $12.53 billion for the current quarter points to a year-over-year change of +12.4%. The $50.49 billion and $55.02 billion estimates for the current and next fiscal years indicate changes of +13.9% and +9%, respectively.

Last Reported Results and Surprise HistoryAbbott reported revenues of $11.16 billion in the last reported quarter, representing a year-over-year change of +7.8%. EPS of $1.15 for the same period compares with $1.09 a year ago.

Compared to the Zacks Consensus Estimate of $11.02 billion, the reported revenues represent a surprise of +1.31%. The EPS surprise was +0.88%.

Over the last four quarters, Abbott surpassed consensus EPS estimates two times. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Abbott is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

On June 02, 2026, we take a closer look at the DCF analysis for Abbott Laboratories ABT . The stock has experienced notable price performance, with a year-to-date decline of 29.1% and a one-year drop of 32.9%. Below are some key points from our analysis:

DCF Earnings-based intrinsic value of $92.77 compared to the current price of $87.78, indicating a margin of safety of 5.4%. DCF Free Cash Flow (FCF)-based intrinsic value stands at $74.67, providing a contrasting perspective. GF Score™ of 76/100 suggests a reliable foundation for the DCF inputs. What Is ABT Worth? DCF Earnings-Based Model The DCF earnings-based model for Abbott Laboratories incorporates a two-stage growth approach. In the first stage, we project earnings growth for the next ten years, followed by a terminal growth phase. The assumptions used in this model are outlined in the table below:

Parameter Value Current EPS (TTM, excl. non-recurring) $5.21 10-Year Growth Rate 11.6% 10-Year Treasury Rate 4.43% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% In the first stage, we expect the EPS to grow at 11.6% per year for the next ten years, which is then discounted at a rate of 11%. The growth stage value is calculated to be $53.67 per share. In the second stage, we apply a terminal growth rate of 4% for the subsequent ten years, discounted at the same rate, yielding a terminal stage value of $39.10 per share. The summary of these calculations is presented below:

Stage Description Value Growth Stage (Years 1-10) EPS growing at 11.6%, discounted at 11% $53.67 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $39.10 Intrinsic Value Growth + Terminal $92.77 Comparing the current price of $87.78 with the intrinsic value of $92.77 indicates that Abbott Laboratories is fairly valued, with a margin of safety of 5.4%. It is important to note that GuruFocus uses EPS excluding non-recurring items, as research indicates that stock prices correlate more closely with earnings than with free cash flow. For further calculations, you can visit the ABT DCF Calculator.

What Does the Free Cash Flow DCF Say? In addition to the earnings-based DCF model, we also evaluate Abbott Laboratories using a Free Cash Flow (FCF)-based approach. The intrinsic value derived from this model is $74.67. When comparing this with the earnings-based intrinsic value of $92.77, we observe a divergence in perspectives. The FCF model suggests that the stock is fairly valued with a margin of safety of -17.6%, indicating a potential cautionary note for investors.

How Does GF Value™ Compare to the DCF Models? The GF Value™ for Abbott Laboratories stands at $128.46, providing a third perspective on the valuation. GF Value™ is GuruFocus' proprietary measure, calculated based on historical trading multiples, past business growth, and future performance estimates. While the DCF earnings-based model suggests fair valuation, the GF Value™ indicates that the stock is undervalued by approximately 31.7%. This discrepancy highlights the importance of considering multiple valuation methods. For more insights, visit the GF Value™ page.

What Does ABT's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021). Below is a summary of Abbott Laboratories' GF Score™ metrics:

Metric Rating GF Score™ 76/100 Financial Strength 6/10 Profitability 8/10 Growth 8/10 Valuation 4/10 Momentum 2/10 With a predictability rating of 0/5 stars, it is essential to recognize that higher predictability typically correlates with more reliable DCF model outputs. For more details, visit the ABT stock page.

Key Assumptions and Limitations It is important to note that DCF models are highly sensitive to growth rate and discount rate assumptions. Stocks with low predictability ratings, such as Abbott Laboratories, tend to produce less reliable DCF estimates. Additionally, the terminal growth rate of 4% is a simplifying assumption that may not fully capture future market conditions.

What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find that Abbott Laboratories is fairly valued according to the earnings-based DCF model, while the FCF model suggests caution. The GF Value™ indicates that the stock is undervalued. Overall, the consensus points towards a fair valuation status. For the full DCF analysis, visit the ABT DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.

Frequently Asked Questions What is ABT's intrinsic value based on DCF?

[Answer: earnings-based $92.78, FCF-based $74.67]

Is ABT overvalued or undervalued?

[Answer using DCF + GF Value™ consensus]

How reliable is the DCF model for ABT?

[Answer using predictability rank 0/5]

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

People stand next to a logo of Abbott at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Purchase Licensing Rights, opens new tab

CompaniesNEW YORK, June 4 (Reuters) - Abbott Laboratories (ABT.N), opens new tab must defend against a proposed class-action lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain ​nutrition drinks were "clinically proven" to help children grow taller, a federal judge ‌ruled on Thursday.

U.S. District Judge Paul Engelmayer said that while Abbott's claim that PediaSure was "clinically proven to help kids grow" didn't specify the type of growth, its use on labels of a cartoon giraffe ​and ruler-like marks that climbed to the giraffe's head could readily support a ​belief that "grow" referred to height growth and "gain" referred to weight gain.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

In a ⁠75-page decision, the Manhattan judge also said jurors could find that Abbott's commercials reinforced ​the message that PediaSure promoted height growth, including an ad showing a boy playing basketball ​with taller boys and saying he has "a lot to look up to."

Abbott in a statement called PediaSure's labeling "appropriate" and supported by the evidence.

"PediaSure is a scientifically designed complete and balanced nutrition solution for children ​to help support growth and development," it said. "We’re confident the evidence will ultimately show ​the plaintiff’s allegations are unfounded."

James Denlea, a lawyer for the consumers, said he was pleased with the ‌decision.

PediaSure ⁠is part of the Abbott Park, Illinois-based company's nutritional segment, whose brands also include Pedialyte and Similac.

The lawsuit was filed in May 2023 by Joanne Noriega, a Bronx, New York, grandmother who said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her ​8-year-old grandson.

Noriega said that ​after a year ⁠of drinking two PediaSure drinks per day, her grandson was still short for his age but had become "so overweight" that she stopped ​buying the drinks.

Abbott has said that PediaSure is intended for children, opens new tab ages ​2 to ⁠13, and helps them "grow out of at-risk weight-for-height percentiles (5th-25th percentiles)" within eight weeks.

Engelmayer also excluded some testimony by expert witnesses for both sides.

He rejected Abbott's bid to dismiss testimony by a ⁠Columbia Business ​School professor who said Abbott's marketing made clear ​that "grow" referred to height, and consumers would not see or understand disclaimers that PediaSure was studied in children "at risk" ​of malnutrition.

Reporting by Jonathan Stempel in New York; Editing by Mark Porter and Aurora Ellis

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Diabetic ketoacidosis (DKA) can develop quickly and is not always easy to detect earlyKetone monitoring is not yet routine in diabetes care, which may contribute to missed warning signs of DKA and delays in interventionNearly 60% of pediatric hospitalizations for Type 1 diabetes in the U.S. are associated with DKA1, /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 and Type 2 diabetes. Findings from multiple Abbott studies shared at the American Diabetes Association's (ADA) June 2026 86th Scientific Sessions show sharp increases in DKA-related hospitalizations across all age groups nationwide. The data reinforces that while diabetes technology has advanced significantly, there are opportunities to better detect rising ketones before DKA develops.

Diabetic Ketoacidosis: Often Misunderstood and Difficult to Recognize

DKA develops in people with diabetes when the body does not have enough insulin and begins breaking down fat for energy, causing ketones to rise to dangerous levels in the blood.2 While traditionally associated with Type 1 diabetes, DKA is increasingly affecting people with Type 2 diabetes. The American Diabetes Association notes that high ketone levels can escalate to DKA within hours and, if left untreated, can lead to coma or death.2 Many people living with diabetes aren't familiar with DKA or its symptoms, despite clinical guidance recommending ketone testing during periods of elevated glucose, making it a challenge to detect early.

New DKA Data from Abbott Presented at ADA's Scientific Sessions

At the ADA's Scientific Sessions, Abbott presented findings from multiple studies analyzing hospitalization, admission diagnosis and insurance claims data to better understand how DKA may be challenging to identify, its rising impact among young people, and a growing prevalence in adults with Type 2 diabetes.

DKA may be hard to identify early at hospital admissions: A study of over 100,000 people across the U.S. found that DKA can be difficult to recognize when a person first arrives at the hospital, as early symptoms – such as nausea, fatigue, or stomach pain – overlap with many common illnesses.3 A confirmed diagnosis of DKA depends on blood tests that measure blood sugar, blood pH and/or bicarbonate levels, and ketones, which may not be immediately available at admission.2 These delays highlight the need for approaches to recognize DKA earlier to provide timely care.Better awareness of DKA may help curb hospitalizations: A second study of over 200,000 people showed that between 2017-2024, DKA hospitalization rates among people with Type 1 diabetes increased approximately 24%, rising from 50 to 62 cases per 1,000 individuals. The increase was more pronounced in children than adults.4 Most DKA events led to hospitalization for both children and adults, while severe hypoglycemia rates stayed low and stable, likely due to greater recognition of hypoglycemia and less awareness of DKA risk.4Reducing DKA hospitalizations may improve health outcomes across all ages: One analysis of close to 40,000 pediatric hospitalizations showed DKA now drives nearly 60% of all diabetes-related hospitalizations among youth with Type 1 or Type 2 diabetes.1 Most U.S. hospitalizations among children with diabetes are related to DKA, with the majority requiring inpatient care lasting up to one week and costing up to $38,000 per stay.1 Findings from a separate study with data from millions of people indicate DKA is likely underreported in adults with Type 2 diabetes, and when diagnosed after admission as a secondary condition, is associated with longer hospital stays, higher costs, and increased rates of death.5"These findings from Abbott show that diabetic ketoacidosis remains a growing challenge to identify, as DKA can develop quickly and mimic common illnesses," said Kurt Midyett, M.D., pediatric endocrinologist at Saint Luke's Endocrinology Specialists in Kansas City, Mo. "When early symptoms are misattributed, delays in diagnosis are common and often result in lengthy and costly hospitalization. This data underscores the importance of addressing gaps in recognition to help detect rising ketones before DKA develops."

The Role of Ketone Monitoring in Diabetes Care

Continuous glucose monitors (CGMs) play an essential role in helping people manage their diabetes by providing real-time glucose insights. However, they do not currently measure ketones and DKA can still develop even when glucose levels appear stable.6 Insights from adults living with Type 1 diabetes show that while some people understand the importance of monitoring ketones, testing is often underused. Rising ketones can progress to DKA within hours, so earlier visibility has the potential to prompt action sooner and reduce risk.6

"These new data make clear that preventing diabetic ketoacidosis starts with recognizing risk earlier," said Mahmood Kazemi, M.D., chief medical officer for Abbott's diabetes care business. "DKA remains one of the most preventable emergencies in diabetes care, yet too many people still miss early warning signs when ketones levels begin to rise. These findings underscore the need for better ways to recognize risk sooner and help reduce avoidable hospitalizations."

As an alternative to existing ketone monitoring options, Abbott has developed dual glucose-ketone sensing technology, which combines continuous glucose and ketone monitoring in a single sensor designed to support both daily diabetes management and help to detect rising ketone levels for people living with diabetes. Abbott announced CE Mark for the systems, called Libre Duo and Libre Duo 10 Day, in May 2026. The company has also filed a regulatory submission with the U.S. Food & Drug Administration (FDA). Libre Duo and Libre Duo 10 Day systems are not yet cleared by the FDA or available for sale in the United States.

Frequently Asked Questions

What is diabetic ketoacidosis?

Diabetic ketoacidosis (DKA) occurs when the body doesn't have enough insulin. To get energy, the body starts breaking down fat, which releases acids called ketones into the blood. People in DKA can experience severe dehydration, dangerous changes to potassium and other electrolytes, and coma. Without prompt treatment, DKA can lead to coma or death.

Can people use urine and blood ketone monitors to test ketones?

Urine and blood ketone monitors are available, but they only offer a snapshot in time and depend on individuals or caregivers recognizing symptoms and deciding to test. Many do not check ketones regularly or lack testing supplies, which can delay action. In a study published in the British Medical Journal Open Diabetes Research & Care, 64% of participants do not test for ketones at all, which can lead to rising ketones that may go unnoticed until a medical emergency develops.7

Can a continuous glucose monitor (CGM) provide information that helps prevent diabetic ketoacidosis?

A CGM, like the FreeStyle Libre 3 Plus sensor, can play an important role in diabetes management, but they are not designed to measure ketones. Because rising ketones are a key driver of diabetic ketoacidosis, relying on glucose data alone may not always provide an early warning before diabetic ketoacidosis (DKA) develops. Abbott has developed a dual glucose-ketone sensing technology in the U.S. that is pending FDA clearance.

About Libre:
Abbott continues to pioneer groundbreaking technology to support people living with diabetes. The company revolutionized diabetes care more than 10 years ago with its world-leading Libre continuous glucose monitoring portfolio8, which today is used by more than 8 million people across over 60 countries. People use Libre technology to see their glucose numbers in real-time, providing insights into how food, activity, or insulin impacts their glucose to help them make progress on their health goals. There is full or partial reimbursement for Libre systems in more than 40 countries.8

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.

Important Safety Information: FreeStyle Libre 3 system is for prescription only, for Important Safety Information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

1 Sherr et al. Burden Of Diabetic Ketoacidosis Among Youth With Diabetes: A Hospital Claims Analysis.
2 American Diabetes Association. "Planning for Sick Days." Accessed February 6, 2026. https://diabetes.org/getting-sick-with-diabetes/sick-days.
3 Miller et al. Characterizing the Clinical Presentation of Diabetic Ketoacidosis Hospitalizations in People with Diabetes using Admitting Diagnoses.
4 Trends in the Prevalence of Diabetic Ketoacidosis and Severe Hypoglycemia in Type 1 Diabetes.
5 Galindo et al. Mortality And Costs of Diabetic Ketoacidosis Hospitalizations in People with Type 2 Diabetes: Differences Between Primary Vs. Secondary Diagnosis.
6 Dhatariya, et al. Lancet Diabetes & Endocrinology (2025): https://pubmed.ncbi.nlm.nih.gov/41381175/
7 Hepprich, M., Roser, P., Stiebitz, S., Felix, B., Schultes, B., Schmitz, D., Rutishauser, J., Schubert, S., Aberle, J., & Rudofsky, G. (2023). Awareness and knowledge of diabetic ketoacidosis in people with type 1 diabetes: a cross-sectional, multicenter survey. BMJ open diabetes research & care, 11(6), e003662. https://doi.org/10.1136/bmjdrc-2023-003662
8 Data on File, Abbott Diabetes Care. Data based on the number of patients assigned to each manufacturer.

View original content:https://www.prnewswire.com/news-releases/new-abbott-data-show-many-people-with-diabetes-may-not-recognize-symptoms-of-diabetic-ketoacidosis-302793024.html

SOURCE Abbott

If you're a new investor who's just getting started with investing, it can seem overwhelming trying to determine which stocks to buy. You may be tempted to go with what's hot right now and focus on the latest trends, but that can be risky. Meanwhile, being too conservative and avoiding risk entirely could result in limited returns and may not seem all that worthwhile.

Three stocks that I think can be ideal ones to build up a portfolio around are Visa (V +0.93%), Home Depot (HD +0.73%), and Abbott Laboratories (ABT 1.64%). With this mix of stocks, you'll get three reasonably valued investments that have strong fundamentals and that also pay dividends. Here's a closer look at each one of them.

Image source: Getty Images.

Visa Credit card giant Visa is a no-brainer for long-term investors given its important role in the economy. Its credit cards are accepted worldwide and are used not only by people who may be short of cash, but also by those who want to collect points and benefit from rewards, as well as those who simply prefer not to use cash.

The business is robust and serves a wide range of customers with varying needs. This is also a highly profitable business, with Visa reporting $22 billion in profit over the trailing 12 months, on revenue totaling $43 billion. That translates into an impressive profit margin of 51%.

Today's Change

(

0.93

%) $

2.96

Current Price

$

322.01

Visa's business isn't going anywhere, and with strong financials, it can be an excellent investment to build your portfolio around. It offers a modest dividend that yields 0.8%, which can pad your returns. It trades at a price-to-earnings (P/E) multiple of just under 28, which isn't terribly cheap but is arguably fair given the growth it continues to generate.

Home Depot Another solid business that provides consumers with necessary products and services is Home Depot, an iconic home improvement retailer. This is a store that many people frequent when they're taking on renovations and other projects around the house. It's helpful to not only get the tools you need to do the job, but also to get advice and suggestions on how to go about doing so.

While the retailer has been facing challenges in recent years due to a slowdown in the housing market, its future remains bright given the strong position it has in retail. It also generates some strong margins, with its profits totaling $14 billion over the past four quarters on revenue of $167 billion, which means its profit margin is about 8%. Although that's nowhere near the profitability that Visa generates, it's a solid rate nonetheless.

Today's Change

(

0.73

%) $

2.38

Current Price

$

328.39

At 3%, you're also getting a terrific dividend yield from Home Depot stock that's close to three times the S&P 500 average of just over 1%. Home Depot has also been increasing its dividend over the years, giving investors an incentive to simply buy and hold. The retail stock currently trades at 22 times earnings.

Abbott Laboratories Rounding out this list is a top healthcare company, Abbott Laboratories. The business generates revenue from multiple segments, including diagnostics, medical devices, nutrition, and established pharmaceuticals, with each one on its own bringing in billions of revenue each quarter. That diversification can help provide you with a solid, all-around healthcare stock.

In the trailing 12 months, Abbott has generated $45 billion in sales with profits totaling about $6.3 billion, which means its net margin is approximately 14%. With many ways to grow its business, it can be a valuable stock to hold given its varying growth opportunities and potential. The company recently acquired Exact Sciences, which develops products that can help with cancer screening and testing.

Today's Change

(

-1.64

%) $

-1.47

Current Price

$

88.18

One of the main reasons investors buy shares of Abbott Laboratories is for its dividend, which currently yields 2.8%. Abbott is also a Dividend King, having raised its payout consistently for more than 50 consecutive years. It's a great buy-and-hold investment that you can simply hang on to and forget about. Its P/E ratio currently sits at 25, which is in line with the S&P 500 average.